Sai Life Sciences has successfully commenced the commercial operations at the second phase of its Unit IV facility in Bidar, Karnataka. Operational from 19 June, 2025, the expansion adds approx. 91 kilolitres (kL) of production capacity, completing the total planned addition of around 195 kL as outlined in the company’s prospectus.

With this phase, Unit IV now boasts a total installed capacity of about 640 kL. The enhanced facility is designed to produce registered starting materials (RSM), intermediates, and active pharmaceutical ingredients (APIs) for both clinical and commercial applications. This expansion supports the company’s growing role in the pharmaceutical supply chain.

Sai Life Sciences, headquartered in Hyderabad, is a prominent global contract research, development, and manufacturing organization (CRDMO). The company collaborates with pharmaceutical and biotech innovators to accelerate the discovery, development, and commercialisation of new drugs. It offers integrated solutions in medicinal chemistry, process development, and manufacturing.